Health Care [ 4/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 25 | -0.07 Increased by +25.40% | -0.09 Increased by +17.11% |
| Mar 17, 25 | -0.07 Decreased by -107.61% | -0.08 Increased by +15.36% |
| Nov 12, 24 | -0.07 Increased by +45.23% | -0.09 Increased by +20.89% |
| Aug 12, 24 | -0.09 Increased by +76.32% | -0.16 Increased by +43.75% |
| May 14, 24 | -0.10 Increased by +64.29% | -0.11 Increased by +9.09% |
| Mar 19, 24 | 0.92 Increased by +192.93% | -0.11 Increased by +936.36% |
| Nov 14, 23 | -0.13 Increased by +79.69% | -0.17 Increased by +23.53% |
| Aug 14, 23 | -0.38 Increased by +54.76% | -0.31 Decreased by -22.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 2.30 M Decreased by -32.51% | -21.53 M Increased by +10.52% | Decreased by -935.23% Decreased by -32.58% |
| Dec 31, 24 | 2.02 M Decreased by -43.90% | -18.79 M Decreased by -139.35% | Decreased by -929.03% Decreased by -170.13% |
| Sep 30, 24 | 1.79 M Decreased by -62.33% | -25.52 M Increased by +78.20% | Decreased by -1.43 K% Increased by +42.14% |
| Jun 30, 24 | 1.11 M Decreased by -53.57% | -20.93 M Increased by +14.92% | Decreased by -1.88 K% Decreased by -83.24% |
| Mar 31, 24 | 3.41 M Decreased by -27.52% | -24.06 M Decreased by -19.95% | Decreased by -705.39% Decreased by -65.49% |
| Dec 31, 23 | 3.60 M Increased by +44.04% | 47.74 M Increased by +182.23% | Increased by +1.32 K% Increased by +157.09% |
| Sep 30, 23 | 4.75 M Increased by +N/A% | -117.09 M Decreased by -325.15% | Decreased by -2.47 K% Decreased by N/A% |
| Jun 30, 23 | 2.40 M Increased by +N/A% | -24.60 M Increased by +29.24% | Decreased by -1.03 K% Decreased by N/A% |